Diagnostic and Prognostic Significance of  Ki-67 Immunohistochemical Expression in  Surface Epithelial Ovarian Carcinoma

Mahadevappa, Asha; Krishna, Shruthi Mysore; Vimala, Manjunath Gubbanna

doi:10.7860/jcdr/2017/24350.9381

Cited by 20 publications

(25 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our result indicates no notable differences in the efficacy of curcumin vs. nanocurcumin on the ovarian morphological outcomes. However, nanocurcumin resulted in better outcomes when compared with curcumin in Ki-67 expressions, known prognostic markers, and predictors for chemotherapy outcomes in ovarian cancer ( Mahadevappa et al, 2017 ; Grabowski et al, 2020 ). We believe that a longer duration of treatment with nanocurcumin might result in better overall outcomes and survival in our ovarian cancer model.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Curcumin Nanoparticle Enhances the Anticancer Effect of Cisplatin by Inhibiting PI3K/AKT and JAK/STAT3 Pathway in Rat Ovarian Carcinoma Induced by DMBA

et al. 2021

View full text Add to dashboard Cite

Cisplatin has been used for decades for the treatment of ovarian cancer. However, despite its potent anticancer effect, cisplatin’s efficacy as a single agent was inadequate in patients with advanced stage. Curcumin has been shown to sensitize cisplatin activity in several cancer models. However, the low bioavailability of curcumin has limited its anticancer potential. Hence, nano-formulation of curcumin was developed to increase its therapeutic efficacy in ovarian cancer. The objective of this study was to investigate the mechanism of curcumin nanoparticles given in combination with cisplatin in rat ovarian carcinoma induced by dimethylbenz(a)anthracene (DMBA). The administration of cisplatin and nanocurcumin resulted in a significant reduction in ovarian tumor volume and weight. Furthermore, there were reduction in expressions of Ki67, TGF-β, PI3K, and Akt phosphorylation. Co-treatment of cisplatin and nanocurcumin also reduced JAK expression, STAT3 phosphorylation, and reduced IL-6 concentrations. Altogether, nanocurcumin, given as a co-treatment with cisplatin has therapeutic potential in ovarian cancer models by inhibiting proliferation through downregulation of PI3K/Akt and JAK/STAT3 signaling pathways.

show abstract

Section: Discussionmentioning

confidence: 98%

“…Ki-67 is a nuclear protein used as a proliferation marker ( Mahadevappa et al, 2017 ; Qiu et al, 2019 ). However, in our result, we also observed cytoplasmic staining of Ki-67.…”

Section: Discussionmentioning

confidence: 99%

Curcumin Nanoparticle Enhances the Anticancer Effect of Cisplatin by Inhibiting PI3K/AKT and JAK/STAT3 Pathway in Rat Ovarian Carcinoma Induced by DMBA

et al. 2021

View full text Add to dashboard Cite

show abstract

“…To predict the prognostic features of clear cell carcinoma of the ovary, several markers have been investigated by immunohistochemistry. For example, the Ki-67 labeling index facilitates the diagnostic differentiation of ovarian carcinoma subtypes, thereby predicting prognosis and determining the need for chemotherapy [ 26 ]. Both Ki-67 and MCM2 are proliferation markers.…”

Section: Discussionmentioning

confidence: 99%

Subcellular localization of MCM2 correlates with the prognosis of ovarian clear cell carcinoma

et al. 2018

View full text Add to dashboard Cite

Highly malignant tumors overexpress the minichromosome maintenance 2 (MCM2) protein in the nucleus, which is associated with advanced tumor grade, advanced stage, and poor prognosis. In this study, we showed that MCM2 is highly expressed in clinical samples of ovarian clear cell carcinoma. Although MCM2 expression was mainly localized to the nuclei as in other cancers, a few cases exhibited cytoplasmic localization of MCM2. Surprisingly, tumor samples with cytoplasmic MCM2 demonstrated excellent prognosis, showing 100% survival during the observation period of more than 200 months. However, cases with nuclear expression of MCM2 exhibited approximately 78% 5-year-survival rate. In a previous study, we showed that Friend leukemia virus (FLV) envelope protein gp70 bound to MCM2, impaired its nuclear translocation, and enhanced DNA damage-induced apoptosis in FLV-infected hematopoietic cells with high levels of MCM2. As expected, clear cell carcinoma cells with cytoplasmic expression of MCM2 exhibited significantly higher apoptotic cell ratio than that of cells with nuclear MCM2 expression. In vitro experiments using ovarian cancer cells with cytoplasmic expression of MCM2 demonstrated that transfection of MCM2-ΔN enhanced DNA damage-induced apoptosis. Therefore, cytoplasmic localization of MCM2 significantly correlated with increased apoptosis in clear cell carcinoma cells, resulting in improved prognosis.

show abstract

“…We found Ki67 index >80% was noticed in 30% of cases. Higher Ki67 levels are associated with advanced FIGO staging in the literature 27 .…”

Section: Discussionmentioning

confidence: 95%

Clinico‑morphological aspects and new immunohistochemistry characteristics of ovarian high‑grade serous carcinoma

Popa¹,

COROBEA²,

Cîrstoiu³

et al. 2018

Arch Balk Med Union

View full text Add to dashboard Cite

Diagnostic and Prognostic Significance of Ki-67 Immunohistochemical Expression in Surface Epithelial Ovarian Carcinoma

Cited by 20 publications

References 27 publications

Curcumin Nanoparticle Enhances the Anticancer Effect of Cisplatin by Inhibiting PI3K/AKT and JAK/STAT3 Pathway in Rat Ovarian Carcinoma Induced by DMBA

Curcumin Nanoparticle Enhances the Anticancer Effect of Cisplatin by Inhibiting PI3K/AKT and JAK/STAT3 Pathway in Rat Ovarian Carcinoma Induced by DMBA

Subcellular localization of MCM2 correlates with the prognosis of ovarian clear cell carcinoma

Clinico‑morphological aspects and new immunohistochemistry characteristics of ovarian high‑grade serous carcinoma

Contact Info

Product

Resources

About